Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 14.7% in January

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the recipient of a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 1,318,481 shares, a decrease of 14.7% from the January 15th total of 1,546,371 shares. Based on an average trading volume of 999,462 shares, the short-interest ratio is currently 1.3 days. Approximately 19.6% of the company’s stock are sold short. Approximately 19.6% of the company’s stock are sold short. Based on an average trading volume of 999,462 shares, the short-interest ratio is currently 1.3 days.

Wall Street Analyst Weigh In

GLSI has been the topic of several research reports. Wall Street Zen raised Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. Finally, HC Wainwright raised their target price on Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Greenwich LifeSciences currently has a consensus rating of “Hold” and an average price target of $47.50.

Greenwich LifeSciences Stock Up 4.4%

Greenwich LifeSciences stock opened at $26.85 on Monday. The company’s 50-day moving average price is $22.01 and its 200-day moving average price is $14.40. The company has a market cap of $371.87 million, a PE ratio of -18.39 and a beta of 1.48. Greenwich LifeSciences has a twelve month low of $7.78 and a twelve month high of $34.10.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, hitting the consensus estimate of ($0.30). As a group, sell-side analysts expect that Greenwich LifeSciences will post -0.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel bought 4,600 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were purchased at an average price of $8.37 per share, for a total transaction of $38,502.00. Following the completion of the purchase, the chief executive officer owned 5,588,102 shares in the company, valued at approximately $46,772,413.74. This represents a 0.08% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired 20,600 shares of company stock worth $378,669 in the last ninety days. 51.47% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth about $25,000. Bank of America Corp DE boosted its position in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after buying an additional 1,322 shares during the period. Wells Fargo & Company MN boosted its position in shares of Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after buying an additional 4,102 shares during the period. Rhumbline Advisers grew its stake in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after buying an additional 3,168 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Greenwich LifeSciences in the fourth quarter worth approximately $203,000. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.